Micafungin
Clinical data | |
---|---|
Trade names | Mycamine |
AHFS/Drugs.com | Monograph |
License data |
|
Intravenous | |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99.8% |
Metabolism | Via catechol-O-methyltransferase pathway |
Elimination half-life | 11–17 hours |
Excretion | 40% feces, <15% urine |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Micafungin, sold under the brand name Mycamine, is an
Administered
In August 2023, Mycamine was acquired from Astellas Pharma by Sandoz.[2]
Indications
Micafungin is
Micafungin works by way of concentration-dependent inhibition of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, which is an essential polysaccharide comprising one-third of the majority of Candida spp. cell walls. This decreased glucan production leads to osmotic instability and thus cellular lysis. [3] [4]
Dosage
The metabolism of micafungin occurs hepatically via acryp sulfatase followed by secondary metabolism by a transferase. Precautions should be taken with regards to dosing, as micafungin weakly inhibits CYP3A4.[5][6]
Dosage forms
Micafungin is a natural antifungal product derived from other fungi as a defense mechanism for competition of nutrients, etc. To be specific, micafungin is derived from FR901379, and is produced by Coleophoma empetri.[7][8]
References
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ Dharma RK (28 August 2023). "Sandoz concludes acquisition of Mycamine antifungal agent". Pharmaceutical Technology. Retrieved 29 August 2023.
- PMID 17806055.
- S2CID 31500007.
- S2CID 265942428.
- S2CID 10873612.
- PMID 19132058.
- .
Further reading
- Eschenauer G, Depestel DD, Carver PL (March 2007). "Comparison of echinocandin antifungals". Therapeutics and Clinical Risk Management. 3 (1): 71–97. PMID 18360617.